NasdaqGS:PRAXBiotechs
A Look At Praxis Precision Medicines (PRAX) Valuation After Wider Full Year And Q4 Net Loss
Praxis Precision Medicines (PRAX) recently reported fourth quarter and full year 2025 results, with net loss and loss per share from continuing operations higher than the prior year. This has put the company’s cash burn and pipeline priorities in sharper focus for investors.
See our latest analysis for Praxis Precision Medicines.
The stock has been volatile, with a 1 day share price return of 2.17% and a 90 day share price return of 71.14%. The 1 year total shareholder return is very large,...